Diphtheria-Tetanus-Acellular Pertussis and Inactivated Poliovirus Vaccines Given Separately or Combined for Booster Dosing at 4–6 Years of Age

Black, Steven; Friedland, Leonard R.; Ensor, Kathleen; Weston, Wayde M.; Howe, Barbara J.; Klein, Nicola P.

doi:10.1097/inf.0b013e3181616180

Cited by 21 publications

(7 citation statements)

References 14 publications

(16 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Extended swelling manifested frequently and with moderate to intense grade in most cases. These results are in line with other studies carried out in the same age group [26]. In 2008, Meyer et al published the results of a clinical trial conducted in Germany comparing immunogenicity and reactogenicity of vaccines with full and reduced antigen content administered to children in preschool age (from 4 to 6 years of age).…”

Section: Resultssupporting

confidence: 84%

Booster Vaccination: The Role of Reduced Antigen Content Vaccines as a Preschool Booster

Gabutti

Trucchi

Conversano³

et al. 2014

BioMed Research International

View full text Add to dashboard Cite

The need for boosters for tetanus, diphtheria, pertussis, and polio, starting from preschool age, is related to the waning immune protection conferred by vaccination, the elimination/reduction of natural boosters due to large-scale immunization programs, and the possibility of reintroduction of wild agents from endemic areas. Taking into account the relevance of safety/tolerability in the compliance with vaccination among the population, it have been assessed whether today enough scientific evidences are available to support the use of dTap-IPV booster in preschool age. The review of the literature was conducted using the PubMed search engine. A total of 41 works has been selected; besides, the documentation produced by the World Health Organization, the European Centre for Disease Control, and the Italian Ministry of Health has been consulted. Many recent papers confirm the opportunity to use a low antigenic dose vaccine starting from 4 to 6 years of age. There is also evidence that 10 years after immunization the rate of seroprotected subjects against diphtheria does not differ significantly between those vaccinated with paediatric dose (DTaP) or reduced dose (dTaP or dTap) product. The dTpa vaccine is highly immunogenic for diphtheria toxoids regardless of prior vaccination history (2 + 1 and 3 + 1 schedules).

show abstract

Section: Resultssupporting

confidence: 84%

Booster Vaccination: The Role of Reduced Antigen Content Vaccines as a Preschool Booster

Gabutti

Trucchi

Conversano³

et al. 2014

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…GMC ratio DTPa-IPV group divided by DTPa+IPV group during infancy and childhood [20][21][22][23][24][25] in which the immunogenicity of DTPa-IPV was shown to be comparable to separate administration of existing commercially available DTPa-based and IPV-containing vaccines, with similar tolerability. Notably, the immunogenicity of the DTPa component of the vaccine was within the range previously reported in a Korean population, in which the seroprotection rates against diphtheria and tetanus and the seropositivity rates against pertussis antigens (PT, FHA and PRN) were [20][21][22][23][24][26][27][28][29] , and in 13 years of post-marketing experience when used for primary and/or booster vaccination. The present study demonstrates similar immunogenicity and tolerability in a Korean population, suggesting the vaccine will be similarly effective in preventing illness due to diphtheria, tetanus, pertussis and poliovirus.…”

Section: Discussionmentioning

confidence: 99%

Immunogenicity, Reactogenicity and Safety of a Combined DTPa-IPV Vaccine Compared with Separate DTPa and IPV Vaccines in Healthy Korean Infants

Kim

Ho²,

Shin

et al. 2010

Korean J Pediatr Infect Dis

View full text Add to dashboard Cite

∫∫ , Wavre, BelgiumPurpose : To compare immunogenicity and reactogenicity of a combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine (DTPa-IPV, Infanrix TM IPV, GlaxoSmithKline Biologicals) with co-administration of commercially available DTPa and IPV vaccines at separate injection sites (DTPa+IPV). Methods : A total of 458 infants aged 8-12 weeks were randomized to receive three-dose primary vaccination at 2, 4 and 6 months with DTPa-IPV or DTPa+IPV. Blood samples were collected pre and post vaccination for measurement of immune responses. Reactogenicity was assessed following each dose using diary cards. Results : One month post-dose 3, seroprotection rates for anti-diphtheria, anti-tetanus and anti-poliovirus types 1, 2 and 3 were 99.5% and vaccine response rates to pertussis antigens were at least 98.6% in both DTPa-IPV and DTPa + IPV ≥ groups. Non-inferiority between the groups was demonstrated based on pre-defined statistical criteria. Incidences of both local and systemic symptoms were within the same range across both groups with grade 3 symptoms reported following no more than 4.3% of DTPa-IPV doses and 4.5% of DTPa + IPV doses. Two serious adverse events (both pyrexia) after DTPa-IPV administration were considered vaccine-related. Both infants recovered fully. Conclusion : Combined DTPa-IPV vaccine was immunogenic and well tolerated when used as a three-dose primary vaccination course in Korean infants. DTPa-IPV could be incorporated into the Korean vaccination schedule, reducing the number of injections required to complete primary immunization. (Korean J Pediatr Infect Dis 2010;17:156-168)

show abstract

“…3,[12][13][14] All of these studies showed high persisting antibodies against vaccine antigens with the exception of antibodies against PT. Pertussis toxin, but not FHA and PRN is specific to Bordetella pertussis, thus low circulating anti-PT antibodies indicate the absence of pertussis infection and suggest ongoing effectiveness of DTPa-HBV-IPV/Hib in preventing pertussis disease.…”

mentioning

confidence: 99%

Immunological persistence in 4-6 and 7-9 year olds previously vaccinated in infancy with hexavalent DTPa-HBV-IPV/Hib

Zinke¹,

Disselhoff²,

Gartner³

et al. 2010

Human Vaccines

View full text Add to dashboard Cite

Combination vaccines induce immunity against multiple diseases in a single injection and thus facilitate delivery of complex vaccination schedules. Use of combination vaccines increases both vaccine coverage and the timeliness of vaccination.1 Infanrix hexa TM , the combined hexavalent diphtheria-tetanus-pertussis-hepatitis B-inactivated poliomyelitis-Haemophilus influenzae type b conjugate vaccine [DTPa-HBV-IPV/Hib, GlaxoSmithKline Biologicals (GSK), Rixensart, Belgium] is the only hexavalent vaccine currently licensed for primary and booster vaccination of infants and provides simultaneous protection against six major diseases of childhood. DTPa-HBV-IPV/Hib contains ≥30 IU diphtheria toxoid, ≥40 IU tetanus toxoid, 25 μg pertussis toxin (PT), 25 μg filamentous haemagglutinin (FHA), 8 μg pertactin (PRN), 10 μg recombinant HBsAg, 40D, 8D and 32D antigen units of poliovirus types 1, 2 and 3 respectively and 10 μg Hib polyribosylribitol-phosphate (PRP) conjugated to tetanus toxoid.Background: the combined diphtheria-tetanus-pertussis-hepatitis B-inactivated poliomyelitis-Haemophilus influenzae conjugate vaccine (Dtpa-HBV-IpV/Hib, Infanrix Hexa tM GlaxoSmithKline Biologicals, rixensart, Belgium) is the only hexavalent vaccine currently licensed for primary and booster vaccination of infants and provides simultaneous protection against six major diseases of childhood. the persistence of the immune response in children aged 4-6 and 7-9 years of age previously vaccinated with four doses of Dtpa-HBV-IpV/Hib vaccine was assessed (www.clinical trials.gov.au 106744 NCt00356564 and 106745 NCt00335881).Methods: A blood sample was collected from 403 children, all of whom had received 3-dose primary vaccination and a booster dose in the second year of life with Dtpa-HBV-IpV/Hib, in previous clinical vaccine trials in Germany.results: Mean time from the fourth Dtpa-HBV-IpV/Hib dose until serological follow-up ranged between 3.6 and 6.4 years. After the 4 th Dtpa-HBV-IpV/Hib dose, in subjects who had not received additional booster doses, seroprotective antibody levels persisted up to 9 years of age in ≥90% of subjects for diphtheria, Hib and poliomyelitis, in 77.2% subjects for Hepatitis B and in 64.7% of subjects for tetanus. Anti-pertussis toxin antibodies remained detectable in no more than 38.2% of subjects.Conclusion: With the exception of pt, the combined Dtpa-HBV-IpV/Hib induces long lasting immune response against all vaccine antigens. Falling seropositivity against pt over time supports the recommended administration of a pertussis booster dose in 5-6 year old children in Germany.

show abstract

Diphtheria-Tetanus-Acellular Pertussis and Inactivated Poliovirus Vaccines Given Separately or Combined for Booster Dosing at 4–6 Years of Age

Abstract: The combination DTaP-IPV vaccine provided immunogenicity and reactogenicity that is comparable to separately administered DTaP and IPV vaccines, with the advantage of requiring one less injection.

Cited by 21 publications

References 14 publications

Booster Vaccination: The Role of Reduced Antigen Content Vaccines as a Preschool Booster

Booster Vaccination: The Role of Reduced Antigen Content Vaccines as a Preschool Booster

Immunogenicity, Reactogenicity and Safety of a Combined DTPa-IPV Vaccine Compared with Separate DTPa and IPV Vaccines in Healthy Korean Infants

Immunological persistence in 4-6 and 7-9 year olds previously vaccinated in infancy with hexavalent DTPa-HBV-IPV/Hib

Contact Info

Product

Resources

About